wtf14 Antibody

What is WTF14 antibody and what is its primary target?

WTF14 antibody appears to be related to the TNFRSF14 (Tumor Necrosis Factor Receptor Superfamily Member 14) family, which includes HVEM (Herpesvirus Entry Mediator). These antibodies recognize specific epitopes on their target proteins and are valuable for studying immune system interactions. Based on available data, WTF14 antibody targets human HVEM/TNFRSF14, which plays crucial roles in immune regulation . The antibody binds specifically to the Pro37-Val202 region of the protein, with some recognized mutations (Ser108Thr and Ala140Arg) .

What applications are WTF14 antibodies most commonly used for in research?

WTF14 antibodies have demonstrated utility across multiple research applications, particularly in immunological studies. They are successfully employed in:

• Flow cytometry for detecting HVEM/TNFRSF14 expression on human blood lymphocytes

• Western blot analysis and direct ELISAs for protein detection

• Neutralization/blocking studies to investigate receptor-ligand interactions

• Immunohistochemistry of frozen tissue sections

• Investigation of cellular adhesion and metalloproteinase production by synoviocytes in rheumatoid arthritis research

How should researchers determine the optimal dilution of WTF14 antibody for specific applications?

Determining optimal dilution requires systematic titration experiments tailored to each specific application. For antibodies like WTF14:

• Begin with manufacturer-recommended dilutions as a starting point (if available)

• Perform serial dilutions (typically 1:2, 1:5, 1:10, 1:50, 1:100, 1:500) of the antibody

• Include appropriate positive and negative controls in each experiment

• For flow cytometry: Compare signal-to-noise ratio at each dilution by analyzing fluorescence intensity of positive population versus background

• For Western blots: Evaluate band specificity, intensity, and background at each dilution

• For ELISAs: Generate standard curves at different antibody concentrations to determine optimal detection range

As noted in the literature, "optimal dilutions should be determined by each laboratory for each application" , as variables like sample type, detection system, and experimental conditions impact results.

What controls should be included when using WTF14 antibody in flow cytometry experiments?

Proper controls are critical for antibody-based flow cytometry. For WTF14 antibody experiments, include:

• Isotype control: Use a matched isotype control antibody (e.g., MAB002 for mouse-derived WTF14 antibodies) at the same concentration to assess non-specific binding

• Unstained control: Cells without any antibody to establish autofluorescence baseline

• FMO (Fluorescence Minus One) controls: Include all fluorochromes except WTF14 antibody to establish gating boundaries

• Secondary antibody-only control: If using indirect staining methods (e.g., with Allophycocyanin-conjugated Anti-Mouse IgG Secondary Antibody)

• Positive control: Cells known to express HVEM/TNFRSF14 (e.g., human peripheral blood lymphocytes)

• Negative control: Cell line known not to express the target

This approach follows the protocol described for "Staining Membrane-associated Proteins" when using WTF14 antibody for detection .

How can researchers assess the binding specificity and potential cross-reactivity of WTF14 antibody?

Assessment of binding specificity requires multi-faceted experimental approaches:

• Direct ELISA cross-reactivity testing: Test binding against the target protein and structurally similar proteins. For example, WTF14/HVEM antibodies have shown approximately 5% cross-reactivity with recombinant human CD30 in direct ELISAs .

• Competitive binding assays: Perform dose-dependent competition experiments with unlabeled antibody against labeled antibody.

• TRF (Time-Resolved Fluorescence) assays: Measure inhibition potency of different antibodies to assess specific binding profiles. For example, using a setup similar to that used for HVEM antibodies to measure inhibition of binding to CD160+ CHO-K1 cells .

• Multiple detection methods: Confirm specificity using orthogonal methods (Western blot, immunoprecipitation, flow cytometry) to validate binding characteristics.

• Knockout/knockdown validation: Test antibody on cells where the target has been genetically depleted to confirm absence of signal.

• Epitope mapping: Determine the specific amino acid sequence recognized by the antibody, which can help predict potential cross-reactivity.

What are the considerations for using WTF14 antibody in antibody-dependent cellular cytotoxicity (ADCC) studies?

ADCC is a critical effector function for many therapeutic antibodies. When using WTF14 antibody in ADCC studies, researchers should consider:

• Fc region properties: The Fc region significantly impacts ADCC activity. Different IgG subclasses (IgG1, IgG4) demonstrate varying ADCC potency .

• Fc modifications impact: Consider whether the antibody has modifications like afucosylation or aglycosylation, as these dramatically affect FcγR binding:

  Antibody Modification	Relative murine FcγRIV binding	Relative human FcγRIIIa-158V binding
  Wild-type IgG1	1.00	1.00
  IgG1-Afuco	3.19	3.05
  IgG1-Aglyco	Non-binding	Non-binding

  Table adapted from published data on Fc-modified antibodies

• Effector cells: Selection of appropriate NK cells or other effector cells is crucial. Primary human NK cells may provide different results compared to cell lines.

• ADCC sufficiency: Research has shown that "ADCC is not sufficient for protection" by some antibodies, suggesting multiple mechanisms may be required for full functional effect .

• Assay format selection: E:T (effector-to-target) ratios, incubation times, and detection methods significantly impact results.

• Correlation with neutralization: Consider that some antibodies may exhibit strong ADCC but poor neutralization activity, or vice versa, requiring comprehensive functional evaluation .

What is the recommended approach for generating monoclonal antibodies against novel targets similar to WTF14?

Based on successful approaches in the literature, a comprehensive protocol would include:

• Immunization strategy: Immunize BALB/c mice with synthesized polypeptides representing the target protein or domain. For example, researchers successfully generated a novel monoclonal antibody against IL-14alpha by immunizing mice with "synthesized human IL-14alpha-C polypeptide" .

• Hybridoma generation: Following immunization, harvest splenic B cells and fuse with myeloma cells to create hybridomas.

• Screening: Implement multi-tier screening approaches:

  • Initial screening via ELISA against the immunizing antigen

  • Secondary validation using spot-ELISA and Western blot analysis

  • Confirmation through immunoprecipitation studies

• Characterization: Determine antibody properties including:

  • Subtype identification (e.g., IgG2a/kappa)

  • Affinity constant (Kaff) calculation (e.g., 1.007 × 108 M-1)

  • Cross-reactivity assessment against related proteins

• Sequencing: Perform variable region sequencing to enable future recombinant production and engineering.

• Functional validation: Confirm the antibody recognizes the native protein in relevant experimental systems.

What analytical methods should be employed to characterize antibody quality during early-phase development?

A comprehensive analytical approach for antibody characterization during early development should include:

• Size Exclusion Chromatography (SEC): To assess aggregation, fragmentation, and purity profiles

• Drug-Antibody Ratio (DAR) and distribution analysis: Using Hydrophobic Interaction Chromatography (HIC) and Polymer Reversed Phase (PLRP) chromatography, particularly important for antibody-drug conjugates

• Isoelectric focusing (icIEF): To determine charge variants and isoelectric point

• Capillary Electrophoresis-SDS (CE-SDS): For analysis of reduced and non-reduced samples to assess structural integrity

• Binding kinetics assessment: Using surface plasmon resonance or bio-layer interferometry to determine kon and koff rates

• Immunoreactive fraction determination: To quantify the percentage of antibody capable of binding to target antigen (properly folded and active)

• Glycan profile analysis: Using HILIC or MS-based methods to characterize glycosylation patterns

As noted in development guidelines: "Methods developed immediately for key quality attributes: SEC, DAR and distribution (HIC, PLRP) and icIEF to support quick Process Development start" .

How does the choice of IgG subclass affect the biodistribution and function of antibodies like WTF14?

The selection of IgG subclass has profound impacts on antibody biodistribution and function. Research demonstrates:

• Differential FcγR binding: IgG subclasses exhibit varying affinities for different Fcγ receptors:

  • IgG1 antibodies show stronger FcγR binding (rated as "++") compared to IgG4 (rated as "+")

  • This impacts cell recruitment and effector functions

• Fragment antigen-binding arm exchange: Wild-type IgG4 antibodies can undergo arm exchange (rated as "+"), while IgG1 and modified IgG4 (S228P mutation) do not exhibit this property (rated as "-")

• Biodistribution variations: Different IgG subclasses demonstrate distinct tissue distribution patterns in vivo, affecting their concentration at target sites

• Half-life differences: Variations in recycling via the neonatal Fc receptor (FcRn) can result in different circulation times for different subclasses

• Immunogenicity considerations: Different subclasses may elicit varying levels of anti-drug antibody responses

These factors should be carefully considered when selecting an IgG subclass for specific research or therapeutic applications of antibodies like WTF14 .

What computational approaches can be used to predict and enhance antibody specificity for complex targets?

Advanced computational methods for antibody specificity prediction and enhancement include:

• Biophysics-informed modeling: This approach identifies "different binding modes, each associated with a particular ligand against which the antibodies are either selected or not" . This allows researchers to:

  • Disentangle binding modes associated with chemically similar ligands

  • Design antibodies with customized specificity profiles

  • Generate variants with specific high affinity for particular target ligands

  • Create antibodies with cross-specificity for multiple target ligands

• Energy function optimization: Computational models can generate novel antibody sequences by optimizing energy functions:

  • For cross-specific sequences: "jointly minimize the functions associated with the desired ligand"

  • For specific sequences: "minimize [energy] associated with the desired ligand and maximize the ones associated with undesired ligands"

• Structural mining approaches: Analysis of crystallographic data can reveal:

  • Previously unrealized interfaces between antibodies

  • Recurrent motifs like β-sheet dimers and variable-constant elbow dimers

  • Opportunities for disulfide engineering to trap and investigate interactions

• High-throughput sequencing with computational analysis: This combination enables:

  • Training models on experimentally selected antibodies

  • Predicting outcomes for new ligand combinations

  • Generating antibody variants not present in initial libraries

How can researchers address inconsistent results when using WTF14 antibody in different experimental systems?

Inconsistent results with antibodies like WTF14 can be addressed through systematic troubleshooting:

• Antibody validation verification: Confirm antibody specificity using multiple techniques (Western blot, flow cytometry, ELISA) and positive/negative controls .

• Protocol standardization: Establish detailed SOPs covering:

  • Sample preparation conditions (lysis buffers, fixation methods)

  • Blocking agents and concentrations

  • Antibody concentration and incubation parameters

  • Washing stringency and buffer composition

  • Detection system calibration

• Epitope accessibility assessment: Different sample preparation methods may affect epitope exposure:

  • For flow cytometry: Compare different cell dissociation methods

  • For Western blots: Test multiple denaturation conditions

  • For IHC/ICC: Compare different fixation and antigen retrieval methods

• Batch-to-batch variation monitoring: Implement quality control testing of new antibody lots against reference standards.

• Environmental variables control: Document and standardize:

  • Temperature during incubation steps

  • pH of buffers and solutions

  • Light exposure for photosensitive reagents

  • Freeze-thaw cycles of antibody aliquots

• Cross-platform validation: When possible, confirm findings using orthogonal methods or alternative antibodies against the same target.

What strategies can improve detection sensitivity when working with low-abundance targets using WTF14 antibody?

Enhancing detection sensitivity for low-abundance targets requires multiple optimization strategies:

• Signal amplification systems:

  • Implement tyramide signal amplification (TSA) for immunohistochemistry and immunofluorescence

  • Use biotin-streptavidin systems for amplified detection

  • Employ polymer-based detection systems with multiple secondary antibodies and enzyme molecules

• Sample enrichment techniques:

  • Perform immunoprecipitation to concentrate target proteins before analysis

  • Use subcellular fractionation to reduce sample complexity

  • Implement affinity purification of target-containing complexes

• Reducing background strategies:

  • Optimize blocking protocols with different agents (BSA, serum, commercial blockers)

  • Test different detergents and concentrations in washing buffers

  • Implement longer/more stringent washing steps

  • Pre-adsorb antibodies against potential cross-reactive materials

• Enhanced detection methods:

  • Use high-sensitivity chemiluminescent substrates for Western blots

  • Employ fluorophores with high quantum yield for immunofluorescence

  • Consider specialized equipment (e.g., cooled CCD cameras, spectral flow cytometers)

• Antibody concentration optimization:

  • Perform careful titration experiments to find optimal signal-to-noise ratio

  • Consider longer incubation times at lower antibody concentrations

• Data acquisition optimization:

  • Adjust detector gain settings for maximum sensitivity without saturation

  • Use longer exposure times with appropriate controls for background correction

How can WTF14 antibody variants be engineered for enhanced specificity and affinity?

Engineering WTF14 antibody variants with enhanced properties can be approached through multiple strategies:

• Targeted mutagenesis of CDR regions: Systematic modification of complementarity-determining regions (CDRs), particularly focusing on:

  • CDR3 regions, which contribute significantly to binding specificity

  • Creating libraries with "four consecutive positions of the third complementary determining region (CDR3) systematically varied"

• Phage display optimization: Implement phage-display experiments with:

  • Minimal antibody libraries based on naïve human VH domains

  • Systematic variation of key amino acid positions

  • High-throughput sequencing to analyze variant performance

• Fc engineering for functional enhancement:

  • Introduce specific glycosylation modifications (e.g., afucosylation) to enhance FcγR binding

  • Implement mutations that alter FcγR binding profiles

  • Consider IgG subclass switching to modify effector functions

• Computational design approaches:

  • Employ "biophysics-informed modeling" to predict binding modes

  • Generate antibody variants "with customized specificity profiles"

  • Optimize energy functions associated with desired and undesired ligands

• Disulfide engineering: Introduction of strategic disulfide bonds can:

  • "Enable interactions to be trapped and investigated structurally and functionally"

  • Provide "experimental validation of the interfaces"

  • Create opportunities for biotherapeutic optimization

What are the latest advances in using antibodies like WTF14 in understanding immune system regulation and dysregulation?

Recent advances in antibody research have revealed important insights into immune regulation:

• Role in autoimmune disease mechanisms: Research using IL-14alpha antibodies has demonstrated that "IL-14alpha could enhance an immune response to both TD and TI antigens and induce a phenotype that is very similar to SLE and Sjögren's syndrome, indicating that IL-14alpha may play an important role in autoimmune disease" .

• Discovery of novel antibody interaction interfaces: Structural mining has revealed "previously unrealized interfaces between antibodies" including "β-sheet dimers and variable-constant elbow dimers" that represent "recurrent motifs" in antibody interactions .

• Elucidation of oligomeric interactions: Research has provided "first insight into previously undiscovered oligomeric interactions between antibodies," enabling "new opportunities for their biotherapeutic optimization" .

• Understanding of transient antibody interactions: Studies have revealed that "antibodies utilize transient homotypic interactions to enhance function," providing "insights into their biology and new opportunities for their optimization as drugs" .

• Role in T-cell responses: Research with HVEM/TNFRSF14 antibodies has shown their association with "CD8+ T cell hyporesponsiveness to alloantigen" following cytomegalovirus-induced expression of CD244 after liver transplantation .

• Influence on cellular adhesion and inflammation: Studies have demonstrated that certain antibodies are "up-regulated on B lymphocytes and monocytes in rheumatoid arthritis" and "mediates cellular adhesion and metalloproteinase production by synoviocytes" .

These advances continue to expand our understanding of the complex roles antibodies play in normal immune function and disease pathogenesis.